|
|
|
|
|
Demeclocycline
drug data and news
Demeclocycline drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Demeclocycline | ||
| Brand Names/Synonyms | Bioterciclin; Clortetrin; DMCT; Declomycin; Deganol; Demeclociclina [Inn-Spanish]; Demeclocycline; Demeclocycline Hcl; Demeclocycline Hydrochloride; Demeclocycline [Usan:Ban]; Demeclocyclinum [Inn-Latin]; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracycline Base; Demethylchlortetracycline Hydrochloride; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Elkamicina; HSDB 3051; Ledermycin; Ledermycin Hydrochloride; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Tri-Demethylchlortetracycline | ||
| Indication | For infections caused by the following microorganisms: Rickettsiae: (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox, tick fevers). M.pneumoniae (PPLO, Eaton agent). Agents of psittacosis and ornithosis. Agents of | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Demeclocycline is a tetracycline antibiotic that is commonly prescribed by medical doctors for infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Demeclocycline is also used commonly as a prophylactic treatment for infection by Bacillus anthracis (anthrax). It is also effective against Yersinia pestis and malaria and is also prescribed for the treatment of Lyme disease. Demeclocycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Cells become resistant to Demeclocycline by at least two mechanisms: efflux and ribosomal protection. In efflux, a resistance gene encodes a membrane protein that actively pumps Demeclocycline out of the cell. This is the mechanism of action of the tetracycline resistance gene on the artificial plasmid pBR322. In ribosomal protection, a resistance gene encodes a protein which binds to the ribosome and prevents Demeclocycline from acting on the ribosome. | ||
| Mechanism Of Action | Demeclocycline inhibits cell growth by inhibiting translation. It binds to the site of the ribosome. The binding is reversible in nature. Demeclocycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. | ||
| Demeclocycline News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Anti-bacterial Agents; Tetracyclines; ATC:D06AA01; ATC:J01AA01 | ||
| Absorption | Readily absorbed | ||
| Interactions |
Interactions for Demeclocycline: Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. Breakthrough bleeding has been reported | ||
| Toxicity | LD50=2732 mg/kg (rat) | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 2-(amino-hydroxy-methylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-4,4a,5,5a,6,12a-hexahydrotetracene-1,3,12-trione | ||
| Chemical Formula | C21H21ClN2O8 | ||
| Molecular Weight | 464.853 g/mol | ||
| Smiles String | CN(C)C1C2CC3C(C4=C(C=CC(=C4C(=C3C(=O)C2(C(=O)C(=C(N)O)C1=O)O)O)O)Cl)O | ||
| Melting Point | 220-223 °C | ||
| Water Solubility | 1520 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | -0.08 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 14-24 hours | ||
| Protein Binding [%] | 60-70% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Demeclocycline.html http://www.rxlist.com/cgi/generic3/demeclocycline.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00272 | ||
| CAS Registry Number | 127-33-3 | ||
| KEGG Compound ID | C06942 | ||
| PubChem ID | SID:173448 | ||
| PharmGKB ID | PA449228 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2169924 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |